111 related articles for article (PubMed ID: 23851334)
1. Analysis of targeted viral protein nanoparticles delivered to HER2+ tumors.
Hwang JY; Farkas DL; Medina-Kauwe LK
J Vis Exp; 2013 Jun; (76):. PubMed ID: 23851334
[TBL] [Abstract][Full Text] [Related]
2. Multimodality imaging in vivo for preclinical assessment of tumor-targeted doxorubicin nanoparticles.
Hwang JY; Park J; Kang BJ; Lubow DJ; Chu D; Farkas DL; Shung KK; Medina-Kauwe LK
PLoS One; 2012; 7(4):e34463. PubMed ID: 22509306
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy targeting by DNA capture in viral protein particles.
Agadjanian H; Chu D; Hwang JY; Wachsmann-Hogiu S; Rentsendorj A; Song L; Valluripalli V; Lubow J; Ma J; Sharifi B; Farkas DL; Medina-Kauwe LK
Nanomedicine (Lond); 2012 Mar; 7(3):335-52. PubMed ID: 22385197
[TBL] [Abstract][Full Text] [Related]
4. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z
J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560
[TBL] [Abstract][Full Text] [Related]
5. Sticky Patches on Lipid Nanoparticles Enable the Selective Targeting and Killing of Untargetable Cancer Cells.
Sempkowski M; Zhu C; Menzenski MZ; Kevrekidis IG; Bruchertseifer F; Morgenstern A; Sofou S
Langmuir; 2016 Aug; 32(33):8329-38. PubMed ID: 27468779
[TBL] [Abstract][Full Text] [Related]
6. Human epidermal growth factor receptor-2 antibodies enhance the specificity and anticancer activity of light-sensitive doxorubicin-labeled liposomes.
Li Q; Tang Q; Zhang P; Wang Z; Zhao T; Zhou J; Li H; Ding Q; Li W; Hu F; Du Y; Yuan H; Chen S; Gao J; Zhan J; You J
Biomaterials; 2015 Jul; 57():1-11. PubMed ID: 25956192
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, characterization, and biological verification of anti-HER2 indocyanine green-doxorubicin-loaded polyethyleneimine-coated perfluorocarbon double nanoemulsions for targeted photochemotherapy of breast cancer cells.
Lee YH; Ma YT
J Nanobiotechnology; 2017 May; 15(1):41. PubMed ID: 28521752
[TBL] [Abstract][Full Text] [Related]
8. Targeted Drug Delivery and Image-Guided Therapy of Heterogeneous Ovarian Cancer Using HER2-Targeted Theranostic Nanoparticles.
Satpathy M; Wang L; Zielinski RJ; Qian W; Wang YA; Mohs AM; Kairdolf BA; Ji X; Capala J; Lipowska M; Nie S; Mao H; Yang L
Theranostics; 2019; 9(3):778-795. PubMed ID: 30809308
[TBL] [Abstract][Full Text] [Related]
9. Tumor targeting using anti-her2 immunoliposomes.
Park JW; Kirpotin DB; Hong K; Shalaby R; Shao Y; Nielsen UB; Marks JD; Papahadjopoulos D; Benz CC
J Control Release; 2001 Jul; 74(1-3):95-113. PubMed ID: 11489487
[TBL] [Abstract][Full Text] [Related]
10. Theranostic pH-sensitive nanoparticles for highly efficient targeted delivery of doxorubicin for breast tumor treatment.
Pan C; Liu Y; Zhou M; Wang W; Shi M; Xing M; Liao W
Int J Nanomedicine; 2018; 13():1119-1137. PubMed ID: 29520140
[TBL] [Abstract][Full Text] [Related]
11. Hyperthermia-triggered intracellular delivery of anticancer agent to HER2(+) cells by HER2-specific affibody (ZHER2-GS-Cys)-conjugated thermosensitive liposomes (HER2(+) affisomes).
Smith B; Lyakhov I; Loomis K; Needle D; Baxa U; Yavlovich A; Capala J; Blumenthal R; Puri A
J Control Release; 2011 Jul; 153(2):187-94. PubMed ID: 21501640
[TBL] [Abstract][Full Text] [Related]
12. Masking and triggered unmasking of targeting ligands on liposomal chemotherapy selectively suppress tumor growth in vivo.
Bandekar A; Zhu C; Gomez A; Menzenski MZ; Sempkowski M; Sofou S
Mol Pharm; 2013 Jan; 10(1):152-60. PubMed ID: 23134440
[TBL] [Abstract][Full Text] [Related]
13. Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model.
Zahmatkeshan M; Gheybi F; Rezayat SM; Jaafari MR
Eur J Pharm Sci; 2016 Apr; 86():125-35. PubMed ID: 26972276
[TBL] [Abstract][Full Text] [Related]
14. Impact of tumor HER2/ERBB2 expression level on HER2-targeted liposomal doxorubicin-mediated drug delivery: multiple low-affinity interactions lead to a threshold effect.
Hendriks BS; Klinz SG; Reynolds JG; Espelin CW; Gaddy DF; Wickham TJ
Mol Cancer Ther; 2013 Sep; 12(9):1816-28. PubMed ID: 23723124
[TBL] [Abstract][Full Text] [Related]
15. Targeting, bio distributive and tumor growth inhibiting characterization of anti-HER2 affibody coupling to liposomal doxorubicin using BALB/c mice bearing TUBO tumors.
Akhtari J; Rezayat SM; Teymouri M; Alavizadeh SH; Gheybi F; Badiee A; Jaafari MR
Int J Pharm; 2016 May; 505(1-2):89-95. PubMed ID: 27039149
[TBL] [Abstract][Full Text] [Related]
16. Dual-targeted and pH-sensitive Doxorubicin Prodrug-Microbubble Complex with Ultrasound for Tumor Treatment.
Luo W; Wen G; Yang L; Tang J; Wang J; Wang J; Zhang S; Zhang L; Ma F; Xiao L; Wang Y; Li Y
Theranostics; 2017; 7(2):452-465. PubMed ID: 28255342
[TBL] [Abstract][Full Text] [Related]
17. DNA-affibody nanoparticles for inhibiting breast cancer cells overexpressing HER2.
Zhang Y; Jiang S; Zhang D; Bai X; Hecht SM; Chen S
Chem Commun (Camb); 2017 Jan; 53(3):573-576. PubMed ID: 27975087
[TBL] [Abstract][Full Text] [Related]
18. A novel cancer targeting approach based on estrone anchored stealth liposome for site-specific breast cancer therapy.
Paliwal SR; Paliwal R; Mishra N; Mehta A; Vyas SP
Curr Cancer Drug Targets; 2010 May; 10(3):343-53. PubMed ID: 20370682
[TBL] [Abstract][Full Text] [Related]
19. A small molecule nanodrug consisting of amphiphilic targeting ligand-chemotherapy drug conjugate for targeted cancer therapy.
Mou Q; Ma Y; Zhu X; Yan D
J Control Release; 2016 May; 230():34-44. PubMed ID: 27040815
[TBL] [Abstract][Full Text] [Related]
20. Polymalic acid-based nanobiopolymer provides efficient systemic breast cancer treatment by inhibiting both HER2/neu receptor synthesis and activity.
Inoue S; Ding H; Portilla-Arias J; Hu J; Konda B; Fujita M; Espinoza A; Suhane S; Riley M; Gates M; Patil R; Penichet ML; Ljubimov AV; Black KL; Holler E; Ljubimova JY
Cancer Res; 2011 Feb; 71(4):1454-64. PubMed ID: 21303974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]